Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

Table 1

FDA-approved MoAbs for cancer patients.

Monoclonal antibody	Target	Approved cancer patients	Mode	Year of introduction
Rituximab	CD20	Non-Hodgkin Lymphoma	Chimeric IgG1	1997
Trastuzumab	ErbB2	Breast	Humanized IgG1	1998
Gemtuzumab-ozogamicin	CD33	Acute myeloid leukemia	Humanized IgG4 + ozogamicin	2000
Alemtuzumab	CD52	Chronic lymphocytic leukemia	Humanized IgG1	2001
Ibritumomab tiuxetan	CD20	Non-Hodgkin’s lymphoma	Murine IgG1+Yttrium90	2002
I-Tositumomab	CD20	Non-Hodgkin’s lymphoma	Murine IgG2a+iodine-131	2003
Cetuximab	EGFR	Colorectal Head/Neck	Chimeric IgG1	2003
Bevacizumab	VEGF	Colorectal	Humanized IgG1	2004
Panitumumab	EGFR	Colorectal	Humanized IgG2	2006
Ofatumumab	CD20	Chronic Lymphocytic Leukemia	Human IgG1	2009
Ipilimumab	CTLA-4	Late stage melanoma	Human IgG1	2011